Loading
BH-30236 is an experimental small molecule from BlossomHill Therapeutics, in phase 1 trials for relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndromes.
BH-30236 is a small molecule (oral, macrocyclic) from BlossomHill Therapeutics. An orally bioavailable macrocyclic inhibitor of the CDC-like kinase (CLK) family, designed to modulate aberrant alternative splicing that AML and higher-risk MDS cells exploit to develop resistance to venetoclax, FLT3 inhibitors and chemotherapy. Its furthest stage is phase 1, for relapsed or refractory acute myeloid leukaemia and higher-risk myelodysplastic syndromes. ClinicalTrials.gov registers it in one study linked below. Phase 1/1b first-in-human trial, recruiting (registry checked 3 Nov 2026); tested alone and with venetoclax. Whether it works in people has not been established unless a trial below reports it.
An orally bioavailable macrocyclic inhibitor of the CDC-like kinase (CLK) family, designed to modulate aberrant alternative splicing that AML and higher-risk MDS cells exploit to develop resistance to venetoclax, FLT3 inhibitors and chemotherapy.
1.BH-30236 slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"BH-30236" OR ABSTRACT:"BH-30236") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about BH-30236, not a curated reading list.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares BlossomHill Therapeutics and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia and the tag pipeline.
Shares BlossomHill Therapeutics and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/